RxDoctor Payments DataLook up a doctor →

Mouhammed Joumaa, MD

Interventional Cardiology · Roseville, MINPI 1316068653

Payments from drug & device makers

$40,960in general payments, 2019–2025

Across 588 payments — averaging $69.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Philips North America LLC$28K
  • Abbott$2K
  • Novartis$2K
  • AstraZeneca$889
  • Amgen$833
  • Johnson & Johnson$808
  • plus $7K from 40 others

What the payments were for

  • Food & beverage$13,233100%
  • Education$270%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$40,960 in reported general payments places this provider in the 70th percentile of 187 interventional cardiology providers in Michigan.

See all interventional cardiology providers in Michigan

Medicare billing

Part B allowed, 2024
$494,696
Medicare patients
965
Services billed
5,885

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban504$609,696
XareltoRivaroxaban370$450,679
EntrestoSacubitril/Valsartan180$232,566
Repatha SureclickEvolocumab157$158,486
FarxigaDapagliflozin Propanediol53$76,176
JardianceEmpagliflozin63$66,653
BrilintaTicagrelor23$19,653
Praluent PenAlirocumab24$16,107
Metoprolol Succinate800$14,129
Amiodarone Hcl109$10,560
Ranolazine ErRanolazine69$9,920
ClopidogrelClopidogrel Bisulfate530$9,670
Rosuvastatin Calcium544$8,761
Diltiazem 24hr Er (Cd)Diltiazem Hcl150$6,622
Carvedilol496$6,448

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$285$609,696504 claims
Johnson & JohnsonXarelto$808$450,679370 claims
NovartisEntresto$1,971$232,566180 claims
AstraZenecaFarxiga, Brilinta$889$95,82976 claims
Boehringer IngelheimJardiance$555$66,65363 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 187 interventional cardiology providers in Michigan.

Other interventional cardiology in Roseville

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →